Clinical Trial Update: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) [Phase 1, Phase 2]

View source ↗

Summary

Regeneron has initiated a first-in-human Phase 1/2 trial of ALN-SOD in adults with ALS caused by SOD1 gene mutations; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ALN-SOD

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene | Phase 1, Phase 2 | Status: RECRUITING